Christopher Ryan Sullivan net worth and biography

Christopher Sullivan Biography and Net Worth

CAO of Avalo Therapeutics

Mr. Sullivan most recently served as the Company’s Chief Accounting Officer and prior to that as Interim Chief Financial Officer, during which time the Company raised approximately $80 million in gross proceeds. Prior to joining Avalo, Mr. Sullivan was the Corporate Controller for Sucampo Pharmaceuticals, a Nasdaq-listed specialty pharmaceuticals company, when it was merged with Mallinckrodt in a $1.2 billion transaction. He also served as the Corporate Controller for OpGen, a Nasdaq-listed diagnostic company, and prior to that was a Senior Manager at Ernst & Young. Mr. Sullivan has a strong public company and life science background, including significant experience with equity and debt capital raises, acquisitions, divestitures, in and out-license transactions, enterprise resource planning implementations, and financial planning and analysis from leading finance and accounting functions at various public biotechnology, molecular diagnostic, and pharmaceutical companies. Mr. Sullivan received dual BS degrees in Finance and Accounting from the University of Maryland, College Park where he graduated magna cum laude, and he is a Certified Public Accountant.

What is Christopher Ryan Sullivan's net worth?: The estimated net worth of Christopher Ryan Sullivan is at least $44.55 as of June 9th, 2023. Mr. Sullivan owns 5 shares of Avalo Therapeutics stock worth more than $45 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Sullivan may own. Additionally, Mr. Sullivan receives a salary of $350,000.00 as CAO at Avalo Therapeutics. Learn More about Christopher Ryan Sullivan's net worth.
How old is Christopher Ryan Sullivan?: Mr. Sullivan is currently 40 years old. There are 3 older executives and no younger executives at Avalo Therapeutics. The oldest executive at Avalo Therapeutics is Dr. Solomon H. Snyder M.D., Founder and Chairman of Scientific Advisory Board, who is 85 years old. Learn More on Christopher Ryan Sullivan's age.
What is Christopher Ryan Sullivan's salary?: As the CAO of Avalo Therapeutics, Inc., Mr. Sullivan earns $350,000.00 per year. The highest earning executive at Avalo Therapeutics is Dr. Garry A. Neil M.D., Chairman of the Board, President & CEO, who commands a salary of $475,000.00 per year. Learn More on Christopher Ryan Sullivan's salary.
How do I contact Christopher Ryan Sullivan?: The corporate mailing address for Mr. Sullivan and other Avalo Therapeutics executives is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. Avalo Therapeutics can also be reached via phone at (410) 522-8707 and via email at [email protected]. Learn More on Christopher Ryan Sullivan's contact information.
Has Christopher Ryan Sullivan been buying or selling shares of Avalo Therapeutics?: Christopher Ryan Sullivan has not been actively trading shares of Avalo Therapeutics during the past quarter. Most recently, on Friday, June 9th, Christopher Ryan Sullivan bought 2 shares of Avalo Therapeutics stock. The stock was acquired at an average cost of $820.80 per share, with a total value of $1,641.60. Following the completion of the transaction, the chief financial officer now directly owns 5 shares of the company's stock, valued at $4,104. Learn More on Christopher Ryan Sullivan's trading history.
Who are Avalo Therapeutics' active insiders?: Avalo Therapeutics' insider roster includes Schond Greenway (CFO), Christopher Sullivan (CAO), and H. Wilkins (Insider). Learn More on Avalo Therapeutics' active insiders.
Are insiders buying or selling shares of Avalo Therapeutics?: In the last year, Avalo Therapeutics insiders bought shares 1 times. They purchased a total of 500 shares worth more than $6,250.00. The most recent insider tranaction occured on November, 12th when Director June Sherie Almenoff bought 500 shares worth more than $6,250.00. Insiders at Avalo Therapeutics own 0.3% of the company. Learn More about insider trades at Avalo Therapeutics.
Information on this page was last updated on 11/12/2024.

Christopher Ryan Sullivan Insider Trading History at Avalo Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/9/2023	Buy	2	$820.80	$1,641.60	5
12/10/2021	Buy	3	$376.80	$1,130.40

Christopher Ryan Sullivan Buying and Selling Activity at Avalo Therapeutics

Avalo Therapeutics Company Overview

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Today's Range

Now: $8.91

$8.67

$9.81

50 Day Range

MA: $11.13

$8.91

$14.44

2 Week Range

Now: $8.91

$3.95

$34.46

Volume

949,861 shs

Average Volume

205,439 shs

Market Capitalization

$92.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Christopher Sullivan Biography and Net Worth

What is Christopher Ryan Sullivan's net worth?

How old is Christopher Ryan Sullivan?

What is Christopher Ryan Sullivan's salary?

How do I contact Christopher Ryan Sullivan?

Has Christopher Ryan Sullivan been buying or selling shares of Avalo Therapeutics?

Who are Avalo Therapeutics' active insiders?

Are insiders buying or selling shares of Avalo Therapeutics?